Literature DB >> 11012880

Functional modulation of the mineralocorticoid receptor by cis-diamminedichloroplatinum (II).

T Iida1, Y Makino, K Okamoto, N Yoshikawa, I Makino, T Nakamura, H Tanaka.   

Abstract

BACKGROUND: Renal salt wasting and hypotension are some of the frequent complications in patients treated with cis-diamminedichloroplatinum (II) (cDDP), and it is suggested that cDDP produces an abnormality in the renin-angiotensin system. However, not only the underlying mechanism but also prophylactic treatment of this cDDP toxicity remains unknown. In the present study, we investigated the molecular mechanism of this cDDP-induced disturbance of renal sodium handling with focusing on the effect of cDDP on mineralocorticoid receptor (MR) function.
METHODS: The effect of cDDP was studied on nuclear translocation, DNA binding activity, and transactivation function of the MR.
RESULTS: In a transient transfection assay, cDDP suppressed MR-dependent reporter gene expression. This cDDP-mediated repression of MR function, at least in part, is suggested to be due to the generation of reactive oxygen species and a subsequent decrease in ligand-dependent nuclear translocation and suppression of the interaction with DNA of the MR. This redox-dependent repression of MR function both in vitro and in vivo was reversed by treatment with reducing reagents. Moreover, cDDP, most possibly via formation of DNA adducts, inhibited MR-DNA interaction in a redox-independent fashion.
CONCLUSIONS: MR function is impaired by cDDP at multiple levels, via redox-dependent and -independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012880     DOI: 10.1046/j.1523-1755.2000.00307.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  2 in total

Review 1.  Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi Jazi; Bahar Mazaheri; Maryam Moeini; Tahereh Safari; Fariba Azarkish; Fatemeh Moslemi; Maryam Maleki; Alireza Rezaei; Shadan Saberi; Aghdas Dehghani; Maryam Malek; Azam Mansouri; Marzieh Ghasemi; Farzaneh Zeinali; Zohreh Zamani; Mitra Navidi; Sima Jilanchi; Soheyla Shirdavani; Farzaneh Ashrafi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

2.  Cisplatin Decreases ENaC Activity Contributing to Renal Salt Wasting Syndrome.

Authors:  Antonio G Soares; Elena Mironova; Crystal R Archer; Jorge Contreras; James D Stockand; Tarek Mohamed Abd El-Aziz
Journal:  Cancers (Basel)       Date:  2020-08-01       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.